Benitec Biopharma (BNTC)

Overall impact
B (78)

Commentary

Benitec Biopharma is a strong overall performer. With a 'B' rating of 77.8 for overall impact (92nd percentile compared to all companies), Benitec Biopharma ranks 17th out of 154 industry peers, behind Eisai, Astellas Pharma, Daiichi Sankyo and 13 others, and ahead of Adamis Pharmaceuticals, Aquinox Pharmaceuticals, Assertio Therapeutics and 134 others. On top material causes for Benitec Biopharma's industry (Pharmaceuticals & Biotech), Benitec Biopharma performs well in Sustainable Use of Water (95.1 score), Child and Maternal Health (83.6), Sustainable Use of Natural Resources (88.6) and 7 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (29.3 score) and Accountable Institutions (39.1).
Impact
Cause BNTC
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
19
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
BNTC
Description
Benitec Biopharma Inc. is a clinical-stage biotechnology company that focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus-based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Material causes
Ethos considers the following causes material for Benitec Biopharma, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.